329 related articles for article (PubMed ID: 9108454)
21. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.
Tanizawa A; Pommier Y
Cancer Res; 1992 Apr; 52(7):1848-54. PubMed ID: 1312902
[TBL] [Abstract][Full Text] [Related]
22. Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase.
Nivens MC; Felder T; Galloway AH; Pena MM; Pouliot JJ; Spencer HT
Cancer Chemother Pharmacol; 2004 Feb; 53(2):107-15. PubMed ID: 14605862
[TBL] [Abstract][Full Text] [Related]
23. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines.
Beidler DR; Chang JY; Zhou BS; Cheng YC
Cancer Res; 1996 Jan; 56(2):345-53. PubMed ID: 8542590
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of camptothecin resistance by human topoisomerase I mutations.
Chrencik JE; Staker BL; Burgin AB; Pourquier P; Pommier Y; Stewart L; Redinbo MR
J Mol Biol; 2004 Jun; 339(4):773-84. PubMed ID: 15165849
[TBL] [Abstract][Full Text] [Related]
25. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.
Fujimori A; Harker WG; Kohlhagen G; Hoki Y; Pommier Y
Cancer Res; 1995 Mar; 55(6):1339-46. PubMed ID: 7882333
[TBL] [Abstract][Full Text] [Related]
26. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
27. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
[TBL] [Abstract][Full Text] [Related]
28. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Yang CJ; Horton JK; Cowan KH; Schneider E
Cancer Res; 1995 Sep; 55(18):4004-9. PubMed ID: 7664272
[TBL] [Abstract][Full Text] [Related]
29. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
30. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK
Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578
[TBL] [Abstract][Full Text] [Related]
31. Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I.
Das BB; Sen N; Roy A; Dasgupta SB; Ganguly A; Mohanta BC; Dinda B; Majumder HK
Nucleic Acids Res; 2006; 34(4):1121-32. PubMed ID: 16488884
[TBL] [Abstract][Full Text] [Related]
32. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro.
Zhao R; al-Said NH; Sternbach DL; Lown JW
J Med Chem; 1997 Jan; 40(2):216-25. PubMed ID: 9003520
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
[TBL] [Abstract][Full Text] [Related]
34. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
35. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells.
Mizutani K; Matsumoto K; Hasegawa N; Deguchi T; Nozawa Y
Exp Oncol; 2006 Sep; 28(3):209-15. PubMed ID: 17080014
[TBL] [Abstract][Full Text] [Related]
36. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Desai SD; Li TK; Rodriguez-Bauman A; Rubin EH; Liu LF
Cancer Res; 2001 Aug; 61(15):5926-32. PubMed ID: 11479235
[TBL] [Abstract][Full Text] [Related]
37. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
38. Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance.
Yanase K; Sugimoto Y; Andoh T; Tsuruo T
Int J Cancer; 1999 Mar; 81(1):134-40. PubMed ID: 10077164
[TBL] [Abstract][Full Text] [Related]
39. Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190.
Samata K; Yamagishi T; Ichihara T; Nanaumi K; Ikeda T; Ikeya H; Kuraishi A; Nakaike S; Kashiwagi K; Igarashi K
Cancer Chemother Pharmacol; 2002 Nov; 50(5):367-72. PubMed ID: 12439594
[TBL] [Abstract][Full Text] [Related]
40. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites.
Tamura H; Kohchi C; Yamada R; Ikeda T; Koiwai O; Patterson E; Keene JD; Okada K; Kjeldsen E; Nishikawa K
Nucleic Acids Res; 1991 Jan; 19(1):69-75. PubMed ID: 1849260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
